Imperial College London
Portrait Picture

Dr Paul Turner

Faculty of Medicine, National Heart & Lung Institute

Reader in Paediatric Allergy & Clinical Immunology
 
 
 
//

Contact

 

+44 (0)20 3312 7754p.turner

 
 
//

Location

 

Children's Clinical Research FacilityCambridge WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Turner:2020:10.1016/j.jaci.2019.12.010,
author = {Turner, P and Fleming, L and Saglani, S and Southern, S and Andrews, NJ and Miller, E and SNIFFLE-4, Study Investigators},
doi = {10.1016/j.jaci.2019.12.010},
journal = {Journal of Allergy and Clinical Immunology},
pages = {1157--1164.e6},
title = {Safety of live attenuated influenza vaccine in children with moderate-severe asthma},
url = {http://dx.doi.org/10.1016/j.jaci.2019.12.010},
volume = {145},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background:Live attenuated influenza vaccine (LAIV) is recommended for annual influenza vaccination in children from age 2 years. However, some guidelines recommend against its use in children with asthma or recurrent wheeze due to concerns over its potential to induce wheezing. Objective: To  assess the safety  of LAIV  in  children  with  moderate-severe  asthma, and  in preschool children with recurrent wheeze. Methods: Prospective, multi-center, open label, phase IV intervention studyin 14 specialist UK clinics.LAIV was administered under medical supervision, with follow-up of asthma symptoms 72 hours and 4 weeks late, using validated questionnaires.Clinical Trials.gov registration NCT02866942, EU Clinical Trials registration 2016-002352-24. Results: 478 young people (median 9.3, range 2–18 years) with physician-diagnosed asthma or recurrent wheeze were recruited, including 208 (44%) prescribed high-dose inhaled corticosteroids and 122 (31%) with severe asthma.There was no significant change in asthma symptoms in the 4 weeks following administration (median change 0,  P=.26, McNemar’s test), with no impact of level of baseline asthma control/symptoms in predicting either a worsening of asthma or exacerbation following LAIV using a regression model. 47 subjects (14.7%, 95%CI 11% to 19.1%) reported a severe asthma exacerbation in the four weeks following immunization, requiring short course of systemic corticosteroids; in four cases, this occurred within 72 hours of vaccine. No association with asthma severity, baseline lung function or asthma control was identified.Conclusions: LAIV appears to be well-tolerated in the vast majority of children with asthma or  recurrent wheeze,  includingthosewhose  asthma  is  categorized  as  severe  or  poorly controlled
AU  - Turner,P
AU  - Fleming,L
AU  - Saglani,S
AU  - Southern,S
AU  - Andrews,NJ
AU  - Miller,E
AU  - SNIFFLE-4,Study Investigators
DO  - 10.1016/j.jaci.2019.12.010
EP  - 1164
PY  - 2020///
SN  - 0091-6749
SP  - 1157
TI  - Safety of live attenuated influenza vaccine in children with moderate-severe asthma
T2  - Journal of Allergy and Clinical Immunology
UR  - http://dx.doi.org/10.1016/j.jaci.2019.12.010
UR  - https://www.sciencedirect.com/science/article/pii/S0091674919317129?via%3Dihub
UR  - http://hdl.handle.net/10044/1/75666
VL  - 145
ER  -
Download